



Name › Zedira GmbH

Address/P.O. Box › Roesslerstrasse 83

Postal Code/City › 64293 Darmstadt

State › Hesse

Contact Person › Dr. Ralf Pasternack

Dr. Martin Hils

(Managing partners)

Telephone › +49-6151-66628-0

Fax › +49-6151-66628-19

Email › contact@zedira.com

Website › www.zedira.com

Social Media › [in](#)

Number of Employees › 16

Founded (year) › 2007

Areas of Activity › **Drug Discovery:**

Transglutaminase inhibitors

| Celiac disease

| Fibrotic disorders

| Anticoagulation

Specialty Reagents:

| Pharma

| Diagnostics

| R+D

Patents › Portfolio covering different classes of small molecule transglutaminase inhibitors

External Collaborations › Licensees: Takeda, Dr. Falk Pharma

Request for Further Collaborations › Zedira offers co-development opportunities in the fields of fibrosis and anticoagulation

Business Unit: Drug Discovery

Design of small molecule transglutaminase inhibitors

TG2 blocker for Celiac Disease: ZED1227


- › First transglutaminase blocker in clinics
- › Proof-of-concept in Celiac Disease (CD)
- › Currently P2b in CD and P2a in NASH/NAFLD
- › Licensed to Takeda and Dr. Falk Pharma

TG2 blocker for fibrotic disorders: ZED3269

- › Oral, systemic availability
- › Unique, reversible mode-of-inhibition

FXIIIa blocker for anticoagulation: ZED3197

- › Novel, untapped target
- › Anticoagulation without increased bleeding tendency



Business Unit: Specialty Reagents

Transglutaminase specialty reagents

Microbial Transglutaminase (Andracon™)

- › Antibody drug conjugate (ADC) generation
- › Tissue scaffold formation

Diagnostic antigens and enzymes

- › TG2, TG3 TG6
- › DGPx1
- › FXIIIa
- › Plasmin
- › ...

Transglutaminase R&D

- › 250 unique products
- › Transglutaminases
- › Assays and substrates
- › Antibodies
- › Inhibitors
- › ...